694533-20-5

Upstream product

• 5228-61-5 5-bromo-2-nitroaniline 
• 1765-93-1 4-fluoroboronic acid 

Downstream Products

• 1449690-87-2 C₂₁H₂₃FN₂O₂ 
• 1179813-46-7 7-(5-(4-fluorophenyl)-1H-benzo[d]imidazol-2-yl)-N-hydroxyheptanamide 

Relevant academic research and scientific papers

HETEROBICYCLIC N-AMINOPHENYL-AMIDES AS INHIBITORS OF HISTONE DEACETYLASE

This invention provides compounds that are inhibitors of HDAC2. The compounds (e.g., compounds according to Formula (I) or any one of Compounds 100-175) accordingly are useful for treating, alleviating, or preventing a condition in a subject such as a neurological disorder, memory or cognitive function disorder or impairment, extinction learning disorder, fungal disease or infection, inflammatory disease, hematological disease, or neoplastic disease, or for improving memory or treating, alleviating, or preventing memory loss or impairment.

Identification of novel HDAC inhibitors through cell based screening and their evaluation as potential anticancer agents

A series of benzimidazole based HDAC inhibitors have been rationally designed, synthesized and screened. The SAR of this new chemotype is described. The lead compound, 11e, showed strong activity in several cellular assays and demonstrated in vivo efficacy in mouse xenograft pancreatic cancer models.